[1] BRENNER H, KLOOR M, POX CP.Colorectal cancer[J].Lancet, 2014, 383(9927):1490. doi: 10.1016/S0140-6736(13)61649-9
[2] 王珺, 梁淑影, 单争争, 等.雷替曲塞二线治疗晚期结直肠癌的疗效分析[J].郑州大学学报(医学版), 2017, 52(3):317.
[3] DESANTIS CE, LIN CC, MARIOTTO AB, et al.Cancer treatment and survivorship statistics, 2014[J].CA Cancer J Clin, 2014, 64(4):252. doi: 10.3322/caac.21235
[4] ROBINSON SM, WILSON CH, BURT AD, et al.Chemotherapy-associated liver injury in patients with colorectal liver metastases:A systematic review and meta-analysis[J].Ann Surg Oncol, 2012, 19(13):4287. doi: 10.1245/s10434-012-2438-8
[5] JI YK, JIN SK, MOO JB, et al.Prospective phase Ⅱ study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis[J].Cancer Chemoth Pham, 2013, 72(1):223. doi: 10.1007/s00280-013-2190-1
[6] KANDUTSCH S, KLINGER M, HACKER S, et al.Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases[J].Eur J Surg Oncol, 2008, 34(11):1231. doi: 10.1016/j.ejso.2008.01.001
[7] MAARTJE AJ, CELIEN V, ALI W, et al.Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases[J].Ann Surg Oncol, 2013, 20(5):1462. doi: 10.1245/s10434-013-2915-8
[8] GRAVALOS C, SALUTA A, GARCIA-GIRON C, et al.A randomized phase Ⅱ study to compare oxaliplatin plus 5-fluorouracil and leucovorin(FOLFOX4) versus oxaliplatin plus raltitrexed(TOMOX) as first-line chemotherapy for advanced colorectal cancer[J].Clin Transl Oncol, 2012, 14(8):606. doi: 10.1007/s12094-012-0843-x
[9] BARNI S, GHIDINI A, COINU A, et al.A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer[J].Anti-cancer Drug, 2014, 25(10):1122. doi: 10.1097/CAD.0000000000000133
[10] 王佳蕾, 李进, 秦叔逵, 等.雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验[J].临床肿瘤学杂志, 2012, 17(1):6. doi: 10.3969/j.issn.1009-0460.2012.01.002
[11] KELLY C, BHUVA N, HARRISON M, et al.Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history[J].Eur J Cancer, 2013, 49(10):2303. doi: 10.1016/j.ejca.2013.03.004
[12] 陈建林, 宋卫峰, 陈栋晖.雷替曲塞治疗晚期结直肠癌临床疗效的Meta分析[J].中国新药与临床杂志, 2010, 29(11):853.
[13] LIU Y, WU W, HONG W, et al.Raltitrexed-based chemotherapy for advanced colorectal cancer[J].Clin Res Hepatol Gas, 2014, 38(2):219. doi: 10.1016/j.clinre.2013.11.006
[14] 蔡承哲.脑栓通胶囊治疗动脉硬化性脑梗死患者的效果观察[J].哈尔滨医药, 2016, 36(1):38.
[15] 吴振海, 曲秀娟.雷替曲塞在晚期结直肠癌中的应用进展[J].中华结直肠疾病电子杂志, 2018, 7(1):62. doi: 10.3877/cma.j.issn.2095-3224.2018.01.013
[16] 余嘉文.雷替曲塞单药二线治疗晚期大肠癌疗效观察[J].中国现代药物应用, 2012, 6(4):18. doi: 10.3969/j.issn.1673-9523.2012.04.011
[17] SHAO GL, LIU RB, DING WB, et al.Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases[J].Anti-cancer Drug, 2018, 29(10):1021. doi: 10.1097/CAD.0000000000000690
[18] 封革, 胡萍, 高金锋, 等.雷替曲塞在晚期结直肠癌三线治疗的临床观察[J].医学信息, 2016, 29(18):69.
[19] 谢达成, 李宁, 王静珏, 等.雷替曲塞联合伊立替康2周方案对比FOLFIRI方案二线治疗晚期结直肠癌的疗效观察[J].临床肿瘤学杂志, 2013, 18(2):140. doi: 10.3969/j.issn.1009-0460.2013.02.011